埃洛图祖马布与波马利多米德,博尔特佐米布和德克萨米松联合使用,用于复发性和耐火性多发性骨髓瘤
Andrew J Yee1,2, Jacob P Laubach3,2, Erica L Campagnaro4
1Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA.
Blood advances
|December 3, 2024
概括
将埃洛图祖马布添加到波马利多米德,博尔特佐米布和德克萨米他 (elo-PVd) 中,对复发性/耐药性多发性骨髓瘤 (MM) 显示出有希望. 这种四重治疗方案在重度预治疗的患者中实现了56.3%的整体应答率.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 临床试验 临床试验
背景情况:
- 埃洛图祖马布是一种单克隆抗体,增强了抗髓瘤疗法,如莱纳利多米德,波马利多米德和博尔特佐米布.
- 在OPTIMISMM研究中,波马利多米德,博尔特佐米布和德克萨米松 (PVd) 在复发性/耐药性多发性骨髓瘤 (MM) 的疗效得到了证明.
研究的目的:
- 评估在患有复发性/耐药性MM的患者的PVD治疗方案 (elo-PVD) 中添加elotuzumab的疗效和安全性.
- 作为主要终点,确定整体反应率 (ORR).
主要方法:
- 一个多中心的第二阶段试验招募了48名患有复发性/耐药性MM的患者,这些患者至少接受过一项先前的治疗,包括列纳利多米德和蛋白酶体抑制剂.
- 埃洛-PVd疗法包括埃洛图祖马布,波马利多米德,博尔特佐米布和德克萨米他,在28天的周期内使用.
- 资格标准包括先前接触过波马利多米德,达拉图穆马布或伊萨图西马布.
主要成果:
- 总体响应率 (ORR) 在整体患者人群中为56.3%.
- 无进展生存期 (PFS) 的中位数为10个月.
- 在只接受过一线治疗的患者中,ORR为73.7%,PFS中位数为23.4个月.
结论:
- 埃洛-PVd疗法在复发性/耐药性多发性骨髓瘤中显示出显著的疗效,包括在先前接受过不同治疗的患者中.
- 这种四重治疗方案代表了严重预治疗多发性骨髓瘤患者的潜在新选择,包括那些对抗CD38抗体耐药的患者.
更多相关视频
相关概念视频
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Tumor Immunotherapy
476
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
476
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K

![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
